Table 1.
Patient characteristics and outcomes
| Total (n = 66) | No transfusion (n = 37) | Transfusion (n = 29) | P value | |
|---|---|---|---|---|
| Gender | ||||
| Male | 43 (65.2 %) | 21 (72.4 %) | 22 (59.5 %) | 0.273b |
| Female | 23 (34.8 %) | 8 (27.6 %) | 15 (40.5 %) | |
| Age | 68.5 (39–80) | 66 (39–79) | 70 (42–80) | 0.096a |
| Preoperative jaundice | ||||
| No | 19 (28.8 %) | 14 (37.8 %) | 5 (17.2 %) | 0.067b |
| Yes | 47 (71.2 %) | 23 (62.2 %) | 24 (82.8 %) | |
| Preoperative serum value | ||||
| CA19-9 (U/mL) | 38.5 (3–14,567) | 20 (3–14,567) | 62 (3–6666) | 0.039a, * |
| ICG-R15 ( %) | 10.75 (0.1–43) | 10.8 (0.7–43.0) | 9.0 (0.1–32.9) | 0.574a |
| FLR ratio ( %) | 47.5 (25.1–86.3) | 46.5 (25.1–86.3) | 50.4 (33.4–77.0) | 0.179a |
| KICG of FLR | 0.070 (0.021–0.323) | 0.069 (0.021–0.179) | 0.073 (0.028–0.323) | 0.275a |
| Preoperative PTPVE | ||||
| No | 34 (51.5 %) | 21 (56.8 %) | 13 (44.8 %) | 0.336b |
| Yes | 32 (48.5 %) | 16 (43.2 %) | 16 (55.2 %) | |
| Operative details | ||||
| Right hepatectomy | 43 (65.2 %) | 24 (64.9 %) | 19 (65.5 %) | 0.337b |
| Left hepatectomy | 19 (28.8 %) | 9 (24.3 %) | 10 (34.5 %) | |
| Right trisectionectomy | 3 (4.5 %) | 3 (8.1 %) | 0 (0.0 %) | |
| Central bisectionectomy | 1 (1.5 %) | 1 (2.7 %) | 0 (0.0 %) | |
| Operative time (min) | 500.5 (307–710) | 470 (307–670) | 590 (390–710) | <0.001a, * |
| Operative blood loss (mL) | 1778.5 (250–11,170) | 1380 (250–2800) | 2910 (990–11,170) | <0.001a, * |
| Postoperative complication (Clavien–Dindo classification) | ||||
| Grade 0 | 4 (6.1 %) | 4 (10.8 %) | 0 (0.0 %) | 0.197b |
| Grade 1 | 9 (13.6 %) | 7 (18.9 %) | 2 (6.9 %) | |
| Grade 2 | 22 (33.3 %) | 10 (27.0 %) | 12 (41.4 %) | |
| Grade 3 | 26 (39.4 %) | 14 (37.8 %) | 12 (41.4 %) | |
| Grade 4 | 4 (6.1 %) | 2 (5.4 %) | 2 (6.9 %) | |
| Grade 5 (Hospital death) | 1 (1.5 %) | 0 (0.0 %) | 1 (3.4 %) | |
| Postoperative max. T-bil (mg/dL) | 3.55 (1.4–14.7) | 2.8 (1.4–10.4) | 4.8 (2.0–14.7) | <0.001a, * |
| Postoperative min. PT ( %) | 66.5 (34–93) | 68 (38–93) | 62 (34–89) | 0.130a |
| Adjuvant chemotherapy | ||||
| Yes | 30 (45.5 %) | 20 (54.1 %) | 10 (34.5 %) | 0.113b |
| No | 36 (54.5 %) | 17 (45.9 %) | 19 (65.5 %) | |
| T-stage (UICC) | ||||
| T1 | 4 (6.1 %) | 3 (8.1 %) | 1 (3.4 %) | 0.542b |
| T2a | 22 (33.3 %) | 14 (37.8 %) | 8 (27.6 %) | |
| T2b | 21 (31.8 %) | 11 (29.7 %) | 10 (34.5 %) | |
| T3 | 12 (18.2 %) | 7 (18.9 %) | 5 (17.2 %) | |
| T4 | 7 (10.6 %) | 2 (5.4 %) | 5 (17.2 %) | |
| Lymph node status | ||||
| Negative | 44 (66.7 %) | 27 (73.0 %) | 17 (58.6 %) | 0.220b |
| Positive | 22 (33.3 %) | 10 (27.0 %) | 12 (41.4 %) | |
| Tumor histological grade | ||||
| Papillary/well differentiated | 16 (24.2 %) | 8 (21.6 %) | 8 (27.6 %) | 0.575b |
| Moderate/poorly differentiated | 50 (75.8 %) | 29 (78.4 %) | 21 (72.4 %) | |
| Microvascular invasion | ||||
| Negative | 18 (27.3 %) | 11 (29.7 %) | 7 (24.1 %) | 0.613b |
| Positive | 48 (72.7 %) | 26 (70.3 %) | 22 (75.9 %) | |
| Lymphovascular invasion | ||||
| Negative | 10 (15.2 %) | 8 (21.6 %) | 2 (6.9 %) | 0.093b |
| Positive | 56 (84.8 %) | 29 (78.4 %) | 27 (93.1 %) | |
| Perineural invasion | ||||
| Negative | 10 (15.2 %) | 7 (18.9 %) | 3 (10.3 %) | 0.271b |
| Positive | 56 (84.8 %) | 30 (81.1 %) | 26 (89.7 %) | |
| Margin status | ||||
| R0 | 54 (81.8 %) | 32 (86.5 %) | 22 (75.9 %) | 0.267b |
| R1 | 12 (18.2 %) | 5 (13.5 %) | 7 (24.1 %) | |
Values are presented as n (%) or median (range)
ICG-R15 indocyanine green retention rate at 15 min, FLR future liver remnant, KICG indocyanine green clearance rate, PTPVE percutaneous transhepatic portal vein embolization, T-bil total bilirubin, PT prothrombin time, UICC Union for International Cancer Control
aMann–Whitney U test
bChi-square test
*P < 0.05